1. Home
  2. TENX vs APCX Comparison

TENX vs APCX Comparison

Compare TENX & APCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TENX
  • APCX
  • Stock Information
  • Founded
  • TENX 1967
  • APCX 2006
  • Country
  • TENX United States
  • APCX United States
  • Employees
  • TENX N/A
  • APCX N/A
  • Industry
  • TENX Biotechnology: Pharmaceutical Preparations
  • APCX Finance: Consumer Services
  • Sector
  • TENX Health Care
  • APCX Finance
  • Exchange
  • TENX Nasdaq
  • APCX Nasdaq
  • Market Cap
  • TENX 19.5M
  • APCX N/A
  • IPO Year
  • TENX N/A
  • APCX N/A
  • Fundamental
  • Price
  • TENX $5.61
  • APCX $0.60
  • Analyst Decision
  • TENX Strong Buy
  • APCX
  • Analyst Count
  • TENX 4
  • APCX 0
  • Target Price
  • TENX $20.67
  • APCX N/A
  • AVG Volume (30 Days)
  • TENX 67.9K
  • APCX 10.7M
  • Earning Date
  • TENX 11-13-2024
  • APCX 11-14-2024
  • Dividend Yield
  • TENX N/A
  • APCX N/A
  • EPS Growth
  • TENX N/A
  • APCX N/A
  • EPS
  • TENX N/A
  • APCX N/A
  • Revenue
  • TENX N/A
  • APCX $365,000.00
  • Revenue This Year
  • TENX N/A
  • APCX $1,315.48
  • Revenue Next Year
  • TENX N/A
  • APCX N/A
  • P/E Ratio
  • TENX N/A
  • APCX N/A
  • Revenue Growth
  • TENX N/A
  • APCX N/A
  • 52 Week Low
  • TENX $2.77
  • APCX $0.31
  • 52 Week High
  • TENX $27.36
  • APCX $2.30
  • Technical
  • Relative Strength Index (RSI)
  • TENX 54.30
  • APCX 60.21
  • Support Level
  • TENX $5.70
  • APCX $0.36
  • Resistance Level
  • TENX $6.01
  • APCX $1.49
  • Average True Range (ATR)
  • TENX 0.47
  • APCX 0.14
  • MACD
  • TENX -0.08
  • APCX 0.02
  • Stochastic Oscillator
  • TENX 12.15
  • APCX 24.32

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: